Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) dropped 5.5% on Tuesday. The company traded as low as $91.04 and last traded at $90.5320. 507,358 shares traded hands during mid-day trading, a decline of 53% from the average session volume of 1,086,653 shares. The stock had previously closed at $95.84.
Analyst Ratings Changes
Several brokerages have recently issued reports on BNTX. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Friday, October 2nd. Argus initiated coverage on BioNTech in a research report on Thursday, October 8th. They issued a “hold” rating on the stock. UBS Group reiterated a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. Morgan Stanley reduced their price target on shares of BioNTech from $115.00 to $114.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. Finally, Berenberg Bank set a $140.00 price target on shares of BioNTech in a research report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BioNTech has a consensus rating of “Moderate Buy” and a consensus price target of $125.69.
View Our Latest Stock Analysis on BioNTech
BioNTech Stock Performance
BioNTech (NASDAQ:BNTX – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business’s quarterly revenue was down 59.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.60) EPS. On average, research analysts predict that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.
Insider Activity at BioNTech
In related news, CEO Ugur Sahin sold 36,209 shares of the firm’s stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the sale, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at $3,453,252.33. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 807,209 shares of company stock valued at $79,246,837 in the last quarter. 19.20% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of BNTX. Hsbc Holdings PLC acquired a new stake in shares of BioNTech during the 4th quarter worth approximately $4,969,000. Bank of America Corp DE increased its holdings in shares of BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after purchasing an additional 166,432 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of BioNTech in the 2nd quarter valued at $2,520,000. Amundi lifted its stake in shares of BioNTech by 24.5% in the 1st quarter. Amundi now owns 129,513 shares of the company’s stock valued at $11,511,000 after purchasing an additional 25,506 shares during the period. Finally, Flossbach Von Storch SE acquired a new position in shares of BioNTech in the 2nd quarter valued at $207,142,000. 15.52% of the stock is owned by institutional investors and hedge funds.
About BioNTech
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.
BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.
Featured Articles
- Five stocks we like better than BioNTech
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
- IonQ Fell 9% on a $1.3 Billion Deal—Is Wall Street Missing Something?
- JPMorgan Earnings Miss Estimates But Reveal Broad-Based Strength
- Flex’s AI Infrastructure Spin-Off Could Unlock Hidden Value
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
